Cargando…

Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study

We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Katagiri, Seiichiro, Akahane, Daigo, Otsuki, Shunsuke, Suto, Arisa, Yamada, Akiko, Suguro, Tamiko, Asano, Michiyo, Yoshizawa, Seiichiro, Tanaka, Yuko, Furuya, Nahoko, Fujimoto, Hiroaki, Okabe, Seiichi, Gotoh, Moritaka, Ito, Yoshikazu, Gotoh, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501552/
https://www.ncbi.nlm.nih.gov/pubmed/36146482
http://dx.doi.org/10.3390/vaccines10091404
_version_ 1784795503125331968
author Katagiri, Seiichiro
Akahane, Daigo
Otsuki, Shunsuke
Suto, Arisa
Yamada, Akiko
Suguro, Tamiko
Asano, Michiyo
Yoshizawa, Seiichiro
Tanaka, Yuko
Furuya, Nahoko
Fujimoto, Hiroaki
Okabe, Seiichi
Gotoh, Moritaka
Ito, Yoshikazu
Gotoh, Akihiko
author_facet Katagiri, Seiichiro
Akahane, Daigo
Otsuki, Shunsuke
Suto, Arisa
Yamada, Akiko
Suguro, Tamiko
Asano, Michiyo
Yoshizawa, Seiichiro
Tanaka, Yuko
Furuya, Nahoko
Fujimoto, Hiroaki
Okabe, Seiichi
Gotoh, Moritaka
Ito, Yoshikazu
Gotoh, Akihiko
author_sort Katagiri, Seiichiro
collection PubMed
description We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals.
format Online
Article
Text
id pubmed-9501552
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95015522022-09-24 Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study Katagiri, Seiichiro Akahane, Daigo Otsuki, Shunsuke Suto, Arisa Yamada, Akiko Suguro, Tamiko Asano, Michiyo Yoshizawa, Seiichiro Tanaka, Yuko Furuya, Nahoko Fujimoto, Hiroaki Okabe, Seiichi Gotoh, Moritaka Ito, Yoshikazu Gotoh, Akihiko Vaccines (Basel) Article We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals. MDPI 2022-08-27 /pmc/articles/PMC9501552/ /pubmed/36146482 http://dx.doi.org/10.3390/vaccines10091404 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Katagiri, Seiichiro
Akahane, Daigo
Otsuki, Shunsuke
Suto, Arisa
Yamada, Akiko
Suguro, Tamiko
Asano, Michiyo
Yoshizawa, Seiichiro
Tanaka, Yuko
Furuya, Nahoko
Fujimoto, Hiroaki
Okabe, Seiichi
Gotoh, Moritaka
Ito, Yoshikazu
Gotoh, Akihiko
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
title Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
title_full Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
title_fullStr Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
title_full_unstemmed Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
title_short Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
title_sort tyrosine kinase inhibitors do not promote a decrease in sars-cov-2 anti-spike igg after bnt162b2 vaccination in chronic myeloid leukemia: a prospective observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501552/
https://www.ncbi.nlm.nih.gov/pubmed/36146482
http://dx.doi.org/10.3390/vaccines10091404
work_keys_str_mv AT katagiriseiichiro tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT akahanedaigo tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT otsukishunsuke tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT sutoarisa tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT yamadaakiko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT sugurotamiko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT asanomichiyo tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT yoshizawaseiichiro tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT tanakayuko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT furuyanahoko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT fujimotohiroaki tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT okabeseiichi tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT gotohmoritaka tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT itoyoshikazu tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy
AT gotohakihiko tyrosinekinaseinhibitorsdonotpromoteadecreaseinsarscov2antispikeiggafterbnt162b2vaccinationinchronicmyeloidleukemiaaprospectiveobservationalstudy